Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis.

The results from this study demonstrated that screening all hypertensive patients for primary aldosteronism from age 40 is cost-effective. The findings argue in favour of screening for primary aldosteronism before the development of severe hypertension in the Australian healthcare setting.